- This event has passed.
NCI Tech Opportunity Webinar: “New Gene Therapy Method for Treating CRX-autosomal Dominant Leber Congenital Amaurosis (LCA)”
November 15, 2022 @ 11:00 AM – 12:00 PM
We invite you to register and join us on November 15 from 11:00 am – 12:00 pm ET for a free NCI technology webinar. Attendees will hear from Drs. Anand Swaroop, Ph.D. and Kamil Kruczek, Ph.D. of the National Eye Institute about a new gene therapy method for treating CRX-autosomal dominant Leber Congenital Amaurosis (LCA). LCA is a rare genetic disease that is responsible for about 20% of all childhood blindness. It’s caused by mutations in any of at least 25 genes that control photoreceptor development or function. LCA has both recessive and dominant forms. Currently, there is an FDA approved gene therapy for treating only one of the recessive forms of LCA caused by mutations in the RPE65 gene. In addition to most recessive forms, the dominant form of LCA with underlying mutations in CRX remains untreatable.
Dr. Swaroop and his team developed a NEW gene therapy treatment for a dominant form of LCA that counteracts dominant mutations in the CRX gene. More specifically, correct CRX gene sequence packaged in an AAV vector was tested in retinal organoids derived from affected patients, resulting in partial recovery of proper photoreceptor development. Importantly, even partial recovery of photoreceptors should help patients regain useful vision. This new technology shows promise as a viable treatment for a currently untreatable rare disease condition.